Jagadish Babu Dasari

Jagadish Babu Dasari

Auto-generated profile, based on publicly available information

Jagadish Babu Dasari

Department of Research and Development, Quanton BioLife Sciences, Ghatsila, Jharkhand, India

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in Cancer Drug Resistance
Verified
Journal Article
Open access
BSBini Chhetri Soren
Bini Chhetri Soren
JDJagadish Babu Dasari
Jagadish Babu Dasari
AOAlessio Ottaviani
Alessio Ottaviani
FLFederico Lacovelli
Federico Lacovelli
PFPaola Fiorani
Paola Fiorani
Cancer Drug Resistance is an open access journal, focusing on pharmacological aspects of drug resistance and its reversal, molecular mechanisms of drug resistance and drug classes, etc. Both clinical and experimental aspects of drug resistance in cancer are included.

1 December 2018
Verified
Journal Article
Closed access
MPM. A. Perrone
M. A. Perrone
JDJ. Babu Dasari
J. Babu Dasari
AIA. Intorcia
A. Intorcia
RMR. Morgagni
R. Morgagni
DSD. Sergi
D. Sergi
FRF. Romeo
F. Romeo

1 January 2014 in International Journal of Basic & Clinical Pharmacology
Verified
Journal Article
Open access
PDF file
GSG Srikanth
G Srikanth
DJD Jagadishbabu
D Jagadishbabu
SJSyed Junied
Syed Junied
MSM Sriharsha
M Sriharsha

1 March 2019 in Archives of Biochemistry and Biophysics
Verified
Journal Article
Closed access
ZWZhenxing Wang
Zhenxing Wang
IDIlda D'ANnessa
Ilda D'ANnessa
CTCinzia Tesauro
Cinzia Tesauro
AOAlessio Ottaviani
Alessio Ottaviani
BSBini Chhetri Soren
Bini Chhetri Soren
PFPaola Fiorani
Paola Fiorani

27 April 2015 in Pharmacology, Toxicology and Biomedical Reports
Verified
Journal Article
Open access
JDJagadish Babu Dasari
Jagadish Babu Dasari
CICristiano Ialongo
Cristiano Ialongo
AKAruna Chandranath Kondakundhi
Aruna Chandranath Kondakundhi
SMSri Harsha Munnamgi
Sri Harsha Munnamgi
SJSyed Juied
Syed Juied

23 June 2026 in Current Drug Targets
Verified
Journal Article
Closed access
PDF file
BSBini Chhetri Soren
Bini Chhetri Soren
SVSoujanya J. Vastrad
Soujanya J. Vastrad
SJSyed Junied
Syed Junied
DSDiya Srikanth
Diya Srikanth
ACAparna Chimalamari
Aparna Chimalamari
JDJagadish Babu Dasari
Jagadish Babu Dasari
Introduction: Malaria is a fatal disease affecting millions of people worldwide, primarily due to infection by Plasmodium falciparum. The emergence of multidrug-resistant parasite strains has necessitated the exploration of novel therapeutic targets. Plasmodium falciparum DNA gyrase A (pfDNA gyrase A), an essential topoisomerase II that is not present in humans, is a promising antimalarial drug target. This study explores the inhibitory potential of three Withania somnifera withanolide derivatives, D, E, and O, against pfDNA gyrase A Methods: An integrated structure-based computational analysis was conducted to explore the inhibitory potential of three withanolides (D, E, and O) against pfDNA gyrase A. Molecular docking, Molecular Dynamics (MD) simulations, and Molecular Mechanics/Generalized Born Surface Area (MM/GBSA) free energy calculations were performed. Pharmacokinetic properties were analysed using SWISS ADME and pkCSM tools. Results: Molecular docking revealed high binding affinities for withanolide D (-9.14kcal/mol), E (-9.73kcal/mol), and O (-9.00kcal/mol), with interactions mediated through key catalytic residues, such as GLU648, LYS647, and TRY590, via hydrogen bonding and hydrophobic contacts. MD simulations confirmed the structural integrity and compactness of the complexes through Root Mean Square Deviation (RMSD), Root Mean Square Fluctuation (RMSF), Radius of Gyration (Rg), and Solvent Accessible Surface Area (SASA). MM/GBSA calculations are further supported by showing the lowest binding free energy for withanolide O and E (ΔGbind =-20.89 and -20.22 kcal/mol). The ADME studies showed favourable pharmacokinetic and physicochemical properties Discussion: This study identifies pfDNA gyrase A as a potential molecular target of Withania somnifera-derived withanolides and elucidates their inhibitory mechanism. Withanolides O and E exhibited strong binding affinity, favorable energetics, and distinct dynamic effects, acting through activesite occlusion and allosteric modulation, respectively. Molecular dynamics and free-energy analyses suggest that effective inhibition results from both structural stabilization and the disruption of critical enzyme motions. Conclusion: Withanolide derivatives were identified as promising inhibitors of pfDNA gyrase A, highlighting their potential as antimalarial agents for addressing drug-resistant malaria.